Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Inventiva ( (IVA) ) has issued an announcement.
The Combined Shareholders’ General Meeting of Inventiva, held on December 11, 2024, resulted in the adoption of all but one resolution, which involved share capital increases for a company savings plan. The meeting confirmed the compensation policy for corporate officers, and the overall acceptance of resolutions demonstrates strong shareholder support for the company’s strategic directions.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company that specializes in developing oral small molecule therapies to address metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs. It is listed on Euronext Paris and Nasdaq under the ticker IVA and operates with a focus on treating conditions that lack effective medical treatments.
YTD Price Performance: -44.03%
Average Trading Volume: 214,376
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $215.9M
For a thorough assessment of IVA stock, go to TipRanks’ Stock Analysis page.
